Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its fourth-quarter and full-year 2025 ...

Merck (known as MSD outside of the United States and Canada) will complete its $9.2 billion acquisition of Cidara ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all the outstanding shares of ...

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...

CAMBRIDGE, England--(BUSINESS WIRE)--Microbiotica, a leader in discovering and developing microbiome-based therapeutics and biomarkers, today announces it has entered into a clinical trial ...

Merck (known as MSD outside the US) has announced an agreement with the US government to provide key products to patients at ...

Commits $1.5 Billion to R&D in China Over The Next 5 Years WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., (NYSE:MRK), known as MSD outside the United States and Canada, today announced ...